Although NK cells of STS patients showed slightly decreased CD69 expression after treatment with NKG2D-CD16 compared to healthy donors (Figure 5F), this trend did not reach statistical significance (p=0.15). The gene discussed is FCGR3B; the disease is telomere syndrome.